THE SCIENCE

Thymosin beta-4 is a naturally occurring 43-amino-acid peptide that interacts with actin and is involved in cellular processes associated with migration and tissue repair. TB-500 is generally described as a synthetic peptide related to this biological system.

Experimental research involving thymosin beta-4 has examined cell migration and tissue repair. Studies have reported effects on processes involved in wound closure, epithelial repair, and cellular movement in laboratory and animal models.

Angiogenesis is the formation of new blood vessels. Preclinical research on thymosin beta-4 has examined increased endothelial-cell activity, vascular sprouting, and blood-vessel formation in experimental models.

• Thymosin beta-4 has been investigated in experimental wound-healing models, including studies involving skin injury and other tissue damage. Research has examined processes such as re-epithelialization, collagen deposition, cell migration, and vascular responses.

The evidence base relevant to TB-500 is predominantly preclinical. Findings from laboratory and animal studies should not be assumed to demonstrate the same effects in humans, and research involving thymosin beta-4 should not automatically be interpreted as evidence for every TB-500 preparation.

The majority of published research on BPC-157 has been conducted in laboratory and animal models. Human clinical evidence remains limited, so findings from preclinical studies should not be assumed to demonstrate the same effects in humans.